Sorrento Therapeutics, Inc.

SRNE

$0.00

+0.00%

2026-09-04 10:02:54 EDT+$0.00

Healthcare

Biotechnology

OTC

Active Trading

Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range ...

Price Action of SRNE

$0.00

+0.00%+$0.00

High—

Low—

52W High-98.6%

Rel. vol—

Interval

Range42m

Volume—SMA5SMA10

—

Key Metrics of SRNE

Snapshot

Latest / TTM · 3 periods

Market Cap

$331,000.00

ROCE

-348.0%

EV / EBITDA

-0.21x

+0.0% YoY

FCF Yield

-92969.4%

-84692.1% YoY

Cash Conversion Cycle

-267.5d

Current Ratio

0.29

Quick take

TTM —

Financial Highlights of SRNE

Profitability trend

Latest / TTM · 3 periods

Gross Margin

46.8%

Net Margin

-911.6%

P/E Ratio

-0.00x

n/a

Debt / Equity

-7.23

n/a

Current Ratio

0.29

Dividend Yield

0.0%

Understanding

TTM —

Calendar of SRNE

Upcoming

Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.44 · Revenue $591.41M · 1 analysts
Jun 30, 2027
Q2 FY2027 · Estimated results
Est. EPS $-0.17 · Revenue $19.75M · 1 analysts

Financial Statements of SRNE

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of SRNE

Acquisitions (A)

Since Sep 7, 2022

Disposals (D)

Since Sep 7, 2022

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of SRNE

2 executives

Name	Title	Compensation	Year Born	Status
Henry H. Ji	Chairman, President & Chief Executive Officer	USD 2,029,893	1964	Active
Scott Schaus	Chief Technology Officer	—	—	Active

Historical Employee Count of SRNE

Current

949

Change

+18.77%

Minimum

799

Maximum

949

Recent Filings

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.37 vs -1.05	-30.5%	-0.17 vs -0.17	0.0%
Revenue Surprise	$62.8M vs $42.2M	+48.8%	$15.0M vs $19.8M	-23.9%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2022	949	10-K	Mar 16, 2023	View
Dec 31, 2021	799	10-K	Mar 11, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Mar 17, 2023	Ji Henry	director, officer: See Remarks	Common Stock	A	19,500	$0.80
Mar 17, 2023	Ji Henry	director, officer: See Remarks	Put Option (obligation to buy)	D	195	$0.80
Dec 21, 2022	Ji Henry	officer: See Remarks	Common Stock	A	300	$5.50
Dec 21, 2022	Ji Henry	officer: See Remarks	Put Option (obligation to buy)	D	3	—
Dec 15, 2022	Ji Henry	officer: See Remarks	Common Stock	A	1,500,000	—

No matching stocks found

Sorrento Therapeutics, Inc.

Price Action of SRNE

Key Metrics of SRNE

Financial Highlights of SRNE

Calendar of SRNE

Upcoming

FY2026 · Estimated annual results

Q2 FY2027 · Estimated results

Financial Statements of SRNE

Insider Transactions of SRNE

Leadership Team of SRNE

Historical Employee Count of SRNE

Recent Filings

Leadership Team of SRNE

Key Metrics of SRNE

Financial Highlights of SRNE

Calendar of SRNE

Upcoming

FY2026 · Estimated annual results

Q2 FY2027 · Estimated results

Financial Statements of SRNE

Insider Transactions of SRNE

Historical Employee Count of SRNE

Recent Filings

Q3 FY2027 · Estimated results

Q4 FY2027 · Estimated results

Recent history

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing